Project Grant K99CA259530
Award Date 5/3/21
Completion Date 7/15/21
Dollars Obligated $136K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. a $645,102 Project Grant (CFDA 93.396, Cancer Biology Research) effective July 1, 2026, through June 30, 2031, to conduct fundamental research on WEE1 kinase cell cycle regulation mechanisms. The award funds basic science research investigating how WEE1 kinase transitions between its dual roles as a cell cycle checkpoint regulator and a substrate for phosphorylation-mediated inactivation at the...
- This $330,543.28 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, was awarded under the Cancer Research Manpower federal grant program (CFDA 93.398) to Dana-Farber Cancer Institute, Inc. for the period of August 16, 2021 through March 31, 2022. The grant funds research aimed at developing a pan-cancer atlas of driver mutations in over 100,000 patients through a hypothesis-driven combined computational and experimental approach....
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $170,394 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective July 1, 2026 through June 30, 2028. The award supports research training and workforce development focused on defining the epigenetic mechanisms underlying neuroendocrine lineage carcinomas, particularly the transformation of prostate adenocarcinoma to small-cell neuroendocrine prostate cancer. The...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $463,279 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective July 1, 2026 through June 30, 2031. The award supports research investigating USP1 (ubiquitin-specific peptidase 1) inhibition as a therapeutic strategy to overcome PARP inhibitor resistance in high-grade serous ovarian cancer (HGSOC). The research deliverables include...
- Federal Grant Award Summary Dana-Farcer Cancer Institute, Inc. received a $718,275 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2026, through June 30, 2031. The award supports fundamental research investigating context-specific pathway dependencies for nuclear envelope (NE) proteins in brain cancer. The project employs large-scale human cancer cell fitness screens and an analytical framework called WEBSTER to...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1.71 million Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, through July 31, 2032. The award funds research into new approaches to targeting cell cycle proteins, specifically cyclin-dependent kinases (CDKs), for cancer treatment. The research addresses three critical therapeutic gaps: developing strategies to induce tumor cell...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Dana-Farber Cancer Institute, Inc. a $683,075 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective March 24, 2026 through February 28, 2031. The award funds research investigating the mitotic function of the 53BP1 protein and its negative regulator TIRR in regulating genome stability and DNA damage repair pathways. The project brings together two principal investigators with...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $737,086 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective July 1, 2026, through June 30, 2031. The award supports fundamental cancer biology research investigating translocation renal cell carcinoma (TRCC), an aggressive RCC subtype lacking approved targeted therapies. The institute will conduct mechanistic studies to validate CDH17, a cell-surface cadherin...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $235,491 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective May 1, 2026, through April 30, 2031. The grant funds a research project titled "The Biology and Phenotypic Consequences of B-Cell Clonality Driven by Mosaic Chromosomal Alterations," which investigates the clinical and biological consequences of high-count monoclonal...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...